StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Citigroup

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byCitigroupHorizon: 1 year29 Sept 2026via Zee Business (Live)

Entry₹1,243.2Inferred
Target₹1,450
Total upside +16.63%
Stop lossNot given
CMP₹1,3801d ago
Active+11.00%+5.07%upside left 11 mo left
Follow Citigroup for new calls(100% target hit, 61 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 20 other Long-term calls on DRREDDYSee 273 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:25 am IST
21 supporting8 neutral15 opposing
Supports the BUY call (21)

Dr Reddy's Laboratories gets Brazil regulator approval for generic semaglutide

NewsCnbc-Tv18·5 Nov · 1w ago

(opens in new tab)

Dr. Reddy's Laboratories has received marketing authorization for its generic semaglutide injection in Brazil.

NSE · Press Release·5 Nov · 1w ago

(opens in new tab)

Dr. Reddy's Laboratories has received marketing authorization from Brazil's ANVISA for its generic semaglutide injection, used for treating type 2 diabetes.

BSE · Company Update·5 Nov · 1w ago

(opens in new tab)

The company received US regulatory approval for a generic HIV prevention injection for distribution in developing countries.

BSE · Company Update·3 Nov · 2w ago

(opens in new tab)

Dr Reddy's Laboratories gets USFDA tentative nod for twice-yearly HIV prevention injection

NewsCnbc-Tv18·2 Nov · 2w ago

(opens in new tab)
Neutral / worth noting (8)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 4w ago

(opens in new tab)
Weighs against the BUY call (15)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·13 Nov · yesterday

5 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·26 Oct · 3w ago

Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginally

NewsEt-Markets·23 Oct · 3w ago

(opens in new tab)

Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates

NewsCnbc-Tv18·23 Oct · 3w ago

(opens in new tab)

Dr. Reddy's reported Q2 FY27 consolidated revenue of Rs 86.7 billion (down 1.5% YoY) and profit after tax of Rs 9.25 billion (down 36% YoY), impacted by lower lenalidomide sales in North America.

NSE · Outcome of Board Meeting·23 Oct · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Citigroup

Every call and its outcome